Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments

The course of anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) therapy has improved impressively. The Food and Drug Administration (FDA) has approved crizotinib (Xalkori, Pfizer) as a first-in-class tyrosine kinase inhibitor (TKI) that demonstrated a substantial objecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Latif, Muhammad, Ashraf, Zaman, Basit, Sulman, Ghaffar, Abdul, Zafar, Muhammad Sohail, Saeed, Aamer, Meo, Sultan Ayoub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080316/
https://www.ncbi.nlm.nih.gov/pubmed/35540549
http://dx.doi.org/10.1039/c8ra01934g

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080316/
https://www.ncbi.nlm.nih.gov/pubmed/35540549
http://dx.doi.org/10.1039/c8ra01934g

Ejemplares similares